Drugs News and Research

RSS

New strategy shows promises for treating RNA-repeat expansion disorders

A new strategy for treating a variety of diseases known as RNA-repeat expansion disorders, which affect millions of people, has shown promise in proof-of-principle tests conducted by scientists at Scripps Research.

8 Nov 2020

Researchers launch clinical trial to assess therapeutic drug monitoring for patients with inflammatory diseases

New research presented at ACR Convergence, the American College Rheumatology's annual meeting, showed that patients with rheumatic diseases whose infliximab treatment was individually assessed and adjusted with a new strategy called therapeutic drug monitoring did not achieve remission at higher rates compared to those who received standard care.

8 Nov 2020

Researchers compare rhesus and cynomolgus macaques for SARS-CoV-2 vaccine trials

A team of researchers at the Biomedical Primate Research Centre based in the Netherlands have aimed to determine the effects of the SARS-CoV-2 pathogen on these monkeys and, subsequently, whether they make good animal models for future research in the area.

8 Nov 2020

Study suggests honey and Nigella sativa expedites viral clearance in COVID-19 patients

A team of researchers from various institutes across Pakistan, Chile, Canada, and the USA recently conducted a clinical trial to investigate the potential effectiveness of a combination of honey and Nigella sativa (HNS) in treating COVID-19 patients. Their study is published on the preprint server medRxiv prior to the scientific peer review process.

8 Nov 2020

Delirium common after hospital discharge in critically ill COVID-19 patients

Anesthesiologist and other researchers from Michigan Medicine, Ann Arbor, New York Medical College, Valhalla and Center for Consciousness Science, University of Michigan Medical School, Ann Arbor, have reported a case series of critically ill coronavirus disease 2019 (COVID-19) patients who have developed neuropsychological symptoms after having been discharged from the hospital.

8 Nov 2020

FDA authorizes marketing of new device intended to provide temporary relief from sleep disturbances

Today, the U.S. Food and Drug Administration permitted marketing of a new device intended for the temporary reduction of sleep disturbance related to nightmares in adults 22 years or older who suffer from nightmare disorder or have nightmares from post-traumatic stress disorder (PTSD).

8 Nov 2020

Biologic or targeted synthetic DMARDs reduce dementia in patients with rheumatoid arthritis

The incidence of dementia in patients with rheumatoid arthritis is lower in patients receiving biologic or targeted synthetic disease modifying antirheumatic drugs (DMARDs) than in patients who receive conventional synthetic DMARDs, according to a new study.

6 Nov 2020

FDA releases final guidance to help identify and prevent insanitary conditions at compounders’ facilities

Protecting patients from exposure to poor quality compounded drugs is a fundamental part of the U.S. Food and Drug Administration's drug compounding program, and we are committed to protecting patients.

6 Nov 2020

New guideline for juvenile idiopathic arthritis gives emphasis to disease-modifying treatments

The American College of Rheumatology will preview the 2021 Guideline for the Treatment of Juvenile Idiopathic Arthritis at ACR Convergence, the ACR's annual meeting.

6 Nov 2020

Lupus patients receiving prophylactic therapy are at high risk for adverse reactions

New research shows that adults with systemic lupus erythematosus, who receive trimethoprim-sulfamethoxazole (TMP-SMX), a prophylactic therapy to help prevent pneumocystis pneumonia, are at high risk for adverse reactions to the drug, particularly if they are also positive for anti-Smith (anti-Sm) antibodies.

6 Nov 2020

Patients with rheumatic diseases reported antimalarial drug shortages during COVID-19

A new study shows that patients with rheumatic diseases across Africa, Southeast Asia, the Americas and Europe had trouble filling their prescriptions of antimalarial drugs, including hydroxychloroquine, during the 2020 global coronavirus pandemic, when antimalarials were touted as a possible COVID-19 treatment.

6 Nov 2020

Survey: Only few children with rheumatic diseases report contracting COVID-19

Results from a large, international survey shows that only a small fraction of children with rheumatic diseases reported contracting COVID-19.

6 Nov 2020

People of color with rheumatic disease have worse COVID-19 outcomes

New research at ACR Convergence, the American College of Rheumatology's annual meeting, reveals that people of color with rheumatic disease have worse health outcomes from COVID-19 infection, are more likely to be hospitalized to treat their coronavirus infection, and are more likely to require invasive ventilator treatment

6 Nov 2020

Hydroxychloroquine not associated with prolonged heart rhythm intervals in RA or lupus patients

New research presented at ACR Convergence, the American College of Rheumatology's annual meeting, discovers that use of hydroxychloroquine, a generic drug, does not cause any significant differences in QTc length or prolonged QTc, key measures of heart rate, in people with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE).

6 Nov 2020

TB screening needed for people on methotrexate who live in at-risk areas

New research presented at ACR Convergence, the American College of Rheumatology's annual meeting, shows that tuberculosis (TB) screening and ongoing clinical care is needed for people on methotrexate who live in areas where the highly infectious illness is common.

6 Nov 2020

Study shows low incidence of COVID-19 infection in people with rheumatic diseases

A new study shows that the COVID-19 infection incidence has been low in people with rheumatic diseases, and most of those infected experience a mild course of illness.

6 Nov 2020

Osteoporosis drug increases bone mineral density in the hip and lumbar spine

New research presented at ACR Convergence, the American College Rheumatology's annual meeting, reveals that romosozumab, an osteoporosis drug, produces substantial gains in bone mineral density in the hip and lumbar spine within one year, and that transitioning patients to a potent antiresorptive drug can lead to even more bone density gains.

6 Nov 2020

Study highlights racial disparities in the care of patients with rheumatoid arthritis

A new study reveals that Black patients with rheumatoid arthritis (RA) were less likely to be prescribed a biologic treatment and more likely to use glucocorticoids, which carry a risk of serious long-term side effects.

6 Nov 2020

Anticoagulant drug linked to greater risk of knee and hip replacements in patients with osteoarthritis

New research presented at ACR Convergence, the American College of Rheumatology's annual meeting, shows that use of warfarin, a vitamin K drug widely prescribed to prevent blood clots, is associated with a significantly greater risk of knee and hip replacements in patients with osteoarthritis.

6 Nov 2020

Commonly prescribed anti-depressant may halt the growth of childhood sarcoma

A new study has found that a commonly prescribed anti-depressant may halt growth of a type of cancer known as childhood sarcoma, at least in mice and laboratory cell experiments.

6 Nov 2020

Drugs News and Research

New strategy shows promises for treating RNA-repeat expansion disorders

Researchers launch clinical trial to assess therapeutic drug monitoring for patients with inflammatory diseases

Researchers compare rhesus and cynomolgus macaques for SARS-CoV-2 vaccine trials

Study suggests honey and Nigella sativa expedites viral clearance in COVID-19 patients

Delirium common after hospital discharge in critically ill COVID-19 patients

FDA authorizes marketing of new device intended to provide temporary relief from sleep disturbances

Biologic or targeted synthetic DMARDs reduce dementia in patients with rheumatoid arthritis

FDA releases final guidance to help identify and prevent insanitary conditions at compounders’ facilities

New guideline for juvenile idiopathic arthritis gives emphasis to disease-modifying treatments

Lupus patients receiving prophylactic therapy are at high risk for adverse reactions

Patients with rheumatic diseases reported antimalarial drug shortages during COVID-19

Survey: Only few children with rheumatic diseases report contracting COVID-19

People of color with rheumatic disease have worse COVID-19 outcomes

Hydroxychloroquine not associated with prolonged heart rhythm intervals in RA or lupus patients

TB screening needed for people on methotrexate who live in at-risk areas

Study shows low incidence of COVID-19 infection in people with rheumatic diseases

Osteoporosis drug increases bone mineral density in the hip and lumbar spine

Study highlights racial disparities in the care of patients with rheumatoid arthritis

Anticoagulant drug linked to greater risk of knee and hip replacements in patients with osteoarthritis

Commonly prescribed anti-depressant may halt the growth of childhood sarcoma

Industry Focus eBook - Cell biology (5th edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News